Caudai C, Pierotti P, Rossetti B, Blanc P, Zazzi M
Eur J Clin Microbiol Infect Dis. 2025; .
PMID: 40011316
DOI: 10.1007/s10096-025-05038-3.
Fedorchenko S, Klimenko Z, Martynovich T, Solianyk I, Suprunenko T
J Virol. 2025; 99(2):e0184324.
PMID: 39840947
PMC: 11852967.
DOI: 10.1128/jvi.01843-24.
Graf C, Sarrazin C, Dietz J
JHEP Rep. 2024; 6(12):101197.
PMID: 39583093
PMC: 11584557.
DOI: 10.1016/j.jhepr.2024.101197.
Shah S, Guerra Veloz M, Agarwal K, Cannon M
JHEP Rep. 2024; 6(11):101093.
PMID: 39434892
PMC: 11490873.
DOI: 10.1016/j.jhepr.2024.101093.
Inzaule S, Easterbrook P, Latona A, Ford N, Irving W, Matthews P
Clin Infect Dis. 2024; 79(6):1437-1446.
PMID: 39361017
PMC: 11650865.
DOI: 10.1093/cid/ciae431.
[Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
Sanchez Suarez M, Martin Roldan A, Cantudo Cuenca M
Rev Esp Quimioter. 2024; 37(3):283-284.
PMID: 38638059
PMC: 11094641.
DOI: 10.37201/req/020.2024.
SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024.
Alghamdi A, Alghamdi H, Alserehi H, Babatin M, Alswat K, Alghamdi M
Saudi J Gastroenterol. 2024; 30(Supp 1):S1-S42.
PMID: 38167232
PMC: 10856511.
DOI: 10.4103/sjg.sjg_333_23.
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.
Martinello M, Bhagani S, Shaw D, Orkin C, Cooke G, Gane E
JHEP Rep. 2023; 5(10):100867.
PMID: 37771545
PMC: 10522905.
DOI: 10.1016/j.jhepr.2023.100867.
Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.
Feld J, Bruneau J, Dore G, Ghany M, Hansen B, Sulkowski M
Clin Infect Dis. 2023; 77(Suppl 3):S262-S269.
PMID: 37579209
PMC: 10425135.
DOI: 10.1093/cid/ciad362.
Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.
Brzdek M, Zarebska-Michaluk D, Invernizzi F, Cilla M, Dobrowolska K, Flisiak R
World J Gastroenterol. 2023; 29(6):949-966.
PMID: 36844142
PMC: 9950869.
DOI: 10.3748/wjg.v29.i6.949.
Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.
Zarebska-Michaluk D, Brzdek M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczynski J
World J Gastroenterol. 2022; 28(45):6380-6396.
PMID: 36533109
PMC: 9753050.
DOI: 10.3748/wjg.v28.i45.6380.
Direct-acting antiviral retreatment patterns for hepatitis C.
Hasan S, Dauner D, Rajpurohit A, Farley J
J Manag Care Spec Pharm. 2022; 28(10):1100-1110.
PMID: 36125057
PMC: 10372973.
DOI: 10.18553/jmcp.2022.28.10.1100.
Breakthroughs in hepatitis C research: from discovery to cure.
Manns M, Maasoumy B
Nat Rev Gastroenterol Hepatol. 2022; 19(8):533-550.
PMID: 35595834
PMC: 9122245.
DOI: 10.1038/s41575-022-00608-8.
Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review.
Green V, Roytman M
Case Reports Hepatol. 2022; 2022:3556780.
PMID: 35309181
PMC: 8933098.
DOI: 10.1155/2022/3556780.
The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting.
Naguib G, Michael T, Elshazly Y, Wahdan M, Mostafa A, Ahmed O
Virusdisease. 2021; 32(3):582-588.
PMID: 34631983
PMC: 8473466.
DOI: 10.1007/s13337-021-00712-4.
Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions.
Ridruejo E, Pereson M, Flichman D, Di Lello F
World J Hepatol. 2021; 13(9):1069-1078.
PMID: 34630875
PMC: 8473504.
DOI: 10.4254/wjh.v13.i9.1069.
A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis.
Saraceni C, Birk J
J Clin Transl Hepatol. 2021; 9(3):409-418.
PMID: 34221927
PMC: 8237136.
DOI: 10.14218/JCTH.2020.00095.
Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?.
Solitano V, Torres M, Pugliese N, Aghemo A
Viruses. 2021; 13(6).
PMID: 34205966
PMC: 8228389.
DOI: 10.3390/v13061048.
HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
Pham L, Pedersen M, Fahnoe U, Fernandez-Antunez C, Humes D, Schonning K
Gut. 2021; 71(3):627-642.
PMID: 33833066
PMC: 8862099.
DOI: 10.1136/gutjnl-2020-323585.
Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review.
Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R
Viruses. 2021; 13(3).
PMID: 33800289
PMC: 8000640.
DOI: 10.3390/v13030432.
